Compare Estee Lauder Companies Inc (EL) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Estee Lauder Companies Inc vs Summit Therapeutics Inc — how do they compare? Estee Lauder Companies Inc trades at $98.12 (market cap $34.17B), while Summit Therapeutics Inc trades at $17.31 (market cap $13.71B). The key difference: Estee Lauder Companies Inc is far larger — about 2.5× Summit Therapeutics Inc's market cap, and Estee Lauder Companies Inc pays a 1.48% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Estee Lauder Companies Inc for 122 Days and Summit Therapeutics Inc for 16 Days on average.
| EL | SMMT | |
|---|---|---|
Market Cap | $34.17B | $13.71B |
Volume | 3,921,497 | 6,173,057 |
Sector | Consumer Staples | Health |
52-Week High | $119.61 | $26.38 |
52-Week Low | $67.23 | $12.43 |
Typical Hold Time | 122 Days | 16 Days |
Enterprise Value | $39.92B | $13.04B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Estée Lauder (EL) trades at $97.81, up 3.56% with recent earnings beats but faces fundamental challenges including a net loss of $1.13B in 2025. The stock shows neutral technical signals with support at $90 and resistance at $98, while analyst consensus remains positive with a $103 price target. Recent developments include AI partnerships and leadership changes aimed at revitalizing the brand.
The outlook hinges on margin recovery and revenue stabilization, with 2026 projections showing a return to profitability. Key risks include competitive pressures and execution of turnaround strategy, but institutional sentiment remains cautiously optimistic given the company's strong brand portfolio and digital initiatives.
Summit Therapeutics (SMMT) trades at $17.44, down 2.84% on the day, with a bullish technical signal from moving averages and strong analyst support. The company shows no revenue but secured a major $2 billion strategic investment from AstraZeneca in September 2026 to advance its cancer drug ivonescimab, driving recent stock volatility and media attention. Financials reflect a pre-revenue biotech profile with significant losses, negative ROE of -192.5%, and cash flow supported by financing activities.
The outlook hinges on clinical success with ivonescimab, offering substantial upside to the $29.33 consensus price target if trials succeed, but high execution risk remains given the lack of revenue and deep losses. Investors face binary outcomes dependent on drug approval and commercialization timelines amid competitive oncology pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Estee Lauder Companies Inc
Estee Lauder is the world leader in the global prestige beauty market, participating across skincare (56% of fiscal 2022 sales), makeup (26%), fragrance (14%), and haircare (4%) categories, with popular brands such as Estee Lauder, Clinique, MAC, La Mer, Jo Malone, Aveda, Bobbi Brown, Too Faced, Origins, Dr. Jart+, and The Ordinary. The firm operates in 150 countries, with 26% of fiscal 2022 revenue stemming from the Americas, 43% from Europe, the Middle East, and Africa, and 31% from Asia-Pacific. The company sells its products through department stores, travel retail, multi-brand specialty beauty stores, brand-dedicated freestanding stores, e-commerce, salons/spas, and perfumeries.
Read more on EL →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
